Idera Pharmaceuticals (IDRA) 2.83 $IDRA
Idera Pharmaceuticals Reports First Quarter 2014 Financial Results and Provides Update on Key Programs and Business Strategy
Business Wire - Tue May 13, 6:01AM CDT
--- Initiated clinical development in Waldenstrom's and DLBCL patients -
Insider Buying On The Rise At These 5 Stocks With Earnings Next Week
at The Street - Thu May 08, 3:33PM CDT
James Dennin, Kapitall: Stocks are rebounding today on strong earnings. We looked for insider buying spikes among stocks with earnings [...]
Why Idera Pharmaceuticals, Inc. Shares Slipped From a Huge Pop Today
Alex Planes, The Motley Fool - Motley Fool - Thu May 08, 12:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Idera Pharmaceuticals, Inc. began...
Idera Announces Agreement with Abbott to Develop a Companion Diagnostic for IMO-8400 in Genetically Defined Forms of B-cell Lymphoma
Business Wire - Thu May 08, 7:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biotechnology company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, announced today that it has entered into an agreement with Abbott, the global healthcare company, for the development of an in vitro companion diagnostic test for use in Idera's clinical development programs to treat certain genetically defined forms of B-cell lymphoma with IMO-8400.
Pre-market Biotech Picks -- Research on Dendreon, Keryx Biopharma, Idera Pharma, and Vertex Pharma
PR Newswire - Wed May 07, 7:00AM CDT
The US markets saw a negative sentiment on Tuesday, May 6, 2014, with the NASDAQ Composite closing at 4,080.76, down 1.38%, the Dow Jones Industrial Average ending the session 0.78% lower at 16,401.02, and the S&P 500 edging 0.90% lower to finish the trading session at 1,867.72. The loss were broad based with nine out of the ten sectors finishing lower. The S&P 500 Health Care Sector Index ended the day at 666.48, down 0.91%, whereas the index has gained 4.08% in the previous three months. Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Idera Pharmaceuticals Inc. (NASDAQ: IDRA) and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on DNDN, KERX, IDRA and VRTX can be downloaded upon signing up at:
Idera Pharmaceuticals to Host Conference Call and Webcast to Report First Quarter 2014 Financial Results and Provide a Detailed Pipeline Review
Business Wire - Tue May 06, 7:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, today announced that the Company will host a conference call and live audio webcast with an accompanying slide presentation at 8:00 a.m. EDT on Tuesday, May 13, 2014 to report its first quarter 2014 financial results. The Company will also provide a detailed review of its pipeline progress, business strategy, recent highlights and upcoming milestones.
Idera Expands Management Team with Three Key Hires
Business Wire - Mon May 05, 7:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, today announced the addition of three new management team members to support the Company's progress in its development pipeline. The Company has appointed Kathryn Haviland, Vice President Rare Diseases; Joseph Lobacki, General Manager of Oncology; and Walter Strapps, Ph.D., Executive Director of RNA Therapeutics.
Global Colitis Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 32 Drug Profiles
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zwv5t/colitis) has announced the addition of the "Colitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Colitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Colitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Colitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Colitis - Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - BioLineRx, Ltd. - Pfizer Inc. - Idera Pharmaceuticals, Inc. - Lpath, Inc. - Protalix BioTherapeutics, Inc. - Galapagos NV - Akebia Therapeutics, Inc. - NasVax Ltd. - Lycera Corp. - Zyngenia, Inc. - N30 Pharmaceuticals - Cognosci, Inc. - Atlantic Healthcare Limited - CellAct Pharma GmbH - Ajinomoto Pharmaceuticals Co., Ltd. Drug Profiles - LT-1009 - PF-06425090 - IMO-3100 - BL-5040 - VGX-1027 - N-6022 - GLPG-0634 - COG-112 - Anti-CD3 Oral Immunotherapy - etanercept biosimilar - N-6547 - BRA-101 - Bioenergetics Program - ARA-290 - CAP-2.1 - CAP-2.2 - Clostridium difficile Vaccine - Cathelicidin - IP-1510 - Helminth-Derived Peptides - Drugs to Inhibit Panx1 for Colitis - Recombinant Cholera Toxin-B - Bi-Specific Anti-TNFalpha/Ang2 Zybody - auranofin - NK-007 - Treg Cells to Inhibit TCR Antagonist for Colitis - Vaccine for Colitis and Respiratory Tract Inflammatory Disorders - APY-0201 - IL-23 P19 Vaccine - AKB-6899 For more information visit http://www.researchandmarkets.com/research/3zwv5t/colitis
Global Moderate Psoriasis Therapeutic Pipeline Review 2014 - 13 Companies Profiled, 19 Drugs Profiled
M2 - Mon Apr 28, 3:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/454xct/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. Scope: - The report provides a snapshot of the global therapeutic landscape of Moderate Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Moderate Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Moderate Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Moderate Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Johnson & Johnson - Boehringer Ingelheim GmbH - Amgen Inc. - Eli Lilly and Company - AbGenomics International, Inc. - ApoPharma Inc. - OPKO Health, Inc. - Idera Pharmaceuticals, Inc. - Almirall, S.A. - Syntrix Biosystems, Inc. - Vascular Biogenics Ltd. - GlycoMar Limited - Avexxin AS Drug Profiles - ixekizumab - LAS-41008 - IMO-3100 - AbGn-168H - VB-201 - lunacalcipol - guselkumab - Apo-805-K1 - BI-655066 - IMO-8400 - MOL-4249 - AVX-001 - AMG-811 - guselkumab - aminopterin sodium - AKP-11 - cyclosporine - GLY-198 - GLYK-5006 For more information visit http://www.researchandmarkets.com/research/454xct/moderate
Will Idera Pharmaceuticals (IDRA) Stock Sustain Today's Rally?
at The Street - Tue Apr 22, 12:21PM CDT
Idera Pharmaceuticals (IDRA) surged Tuesday on a positive day for healthcare stocks after the company had remained relatively flat since last week.
U.S. District Court Judge Nixes Banning of Zogenix's Painkiller in Massachusetts
ACCESSWIRE - Mon Apr 21, 9:42AM CDT
A U.S. District Court judge stopped Massachusetts from banning the sale of Zogenix Inc.'s (NASDAQ: ZGNX) prescription painkiller Zohydro, saying that the decision was based on the principle that federal law superseded the state's action.
Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)
at The Street - Fri Apr 11, 9:10AM CDT
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Top Gainers Technical Data -- Research on BioScrip, E-House China Holdings, MagneGas, and Idera Pharma
PR Newswire - Wed Apr 09, 7:47AM CDT
On Tuesday, April 08, 2014, the US markets saw a positive sentiment, with the NASDAQ Composite closing at 4,112.99, up 0.81%, the Dow Jones Industrial Average ending the session at 16,256.14, up 0.06%, and the S&P 500 edging 0.38% higher to finish the trading session at 1,851.96. The session saw a positive impact from Consumer Discretionary, Energy and Utilities sectors along with a drag from Health Care, Industrials and Telecommunication Services sectors. A number of stocks saw large movements, including BioScrip Inc. (NASDAQ: BIOS), E-House China Holdings Ltd (NYSE: EJ), MagneGas Corp. (NASDAQ: MNGA) and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free technical research on BIOS, EJ, MNGA and IDRA can be downloaded upon signing up at:
Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic MYD88 L265P Mutation
Business Wire - Mon Apr 07, 3:05PM CDT
--- IMO-8400 in Phase 1/2 trial for Waldenstrom's macroglobulinemia -
Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Idera Pharmaceuticals, Inc. Bouncing on Phase 2 Success
Catherine Shaffer, The Motley Fool - Motley Fool - Tue Apr 01, 5:30PM CDT
Idera Pharmaceuticals ' stock market rollercoaster ride left it partially recovered from its 25% plunge just over a week ago upon FDA approval of a competing product developed by Celgene . Idera's plaque psoriasis candidate, IMO-8400, gave good...
Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock
at The Street - Tue Apr 01, 8:48AM CDT
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Why MannKind, Momenta Pharmaceuticals, and Idera Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 31, 7:30PM CDT
Lately, the stock market has turned on every word from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from investors Monday. With Yellen offering a much more...
Idera Soars on Phase II Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:06PM CDT
Idera announced positive top-line data from a phase II study on IMO-8400.
Biggest Biotech Clinical Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 1:30PM CDT
Last week was full of great news for biotechs. Idera Pharmaceuticals finally had some luck with a troubled program. Clovis Oncology took a big step toward treating defined populations with unmet need with a drug and diagnostic combination....
Idera Pharmaceuticals Reports First Quarter 2014 Financial Results and Provides Update on Key Programs and Business Strategy
Business Wire - Tue May 13, 6:01AM CDT
--- Initiated clinical development in Waldenstrom's and DLBCL patients -
Insider Buying On The Rise At These 5 Stocks With Earnings Next Week
at The Street - Thu May 08, 3:33PM CDT
James Dennin, Kapitall: Stocks are rebounding today on strong earnings. We looked for insider buying spikes among stocks with earnings [...]
Why Idera Pharmaceuticals, Inc. Shares Slipped From a Huge Pop Today
Alex Planes, The Motley Fool - Motley Fool - Thu May 08, 12:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Idera Pharmaceuticals, Inc. began...
Idera Announces Agreement with Abbott to Develop a Companion Diagnostic for IMO-8400 in Genetically Defined Forms of B-cell Lymphoma
Business Wire - Thu May 08, 7:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biotechnology company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, announced today that it has entered into an agreement with Abbott, the global healthcare company, for the development of an in vitro companion diagnostic test for use in Idera's clinical development programs to treat certain genetically defined forms of B-cell lymphoma with IMO-8400.
Pre-market Biotech Picks -- Research on Dendreon, Keryx Biopharma, Idera Pharma, and Vertex Pharma
PR Newswire - Wed May 07, 7:00AM CDT
The US markets saw a negative sentiment on Tuesday, May 6, 2014, with the NASDAQ Composite closing at 4,080.76, down 1.38%, the Dow Jones Industrial Average ending the session 0.78% lower at 16,401.02, and the S&P 500 edging 0.90% lower to finish the trading session at 1,867.72. The loss were broad based with nine out of the ten sectors finishing lower. The S&P 500 Health Care Sector Index ended the day at 666.48, down 0.91%, whereas the index has gained 4.08% in the previous three months. Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Idera Pharmaceuticals Inc. (NASDAQ: IDRA) and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on DNDN, KERX, IDRA and VRTX can be downloaded upon signing up at:
Idera Pharmaceuticals to Host Conference Call and Webcast to Report First Quarter 2014 Financial Results and Provide a Detailed Pipeline Review
Business Wire - Tue May 06, 7:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, today announced that the Company will host a conference call and live audio webcast with an accompanying slide presentation at 8:00 a.m. EDT on Tuesday, May 13, 2014 to report its first quarter 2014 financial results. The Company will also provide a detailed review of its pipeline progress, business strategy, recent highlights and upcoming milestones.
Idera Expands Management Team with Three Key Hires
Business Wire - Mon May 05, 7:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, today announced the addition of three new management team members to support the Company's progress in its development pipeline. The Company has appointed Kathryn Haviland, Vice President Rare Diseases; Joseph Lobacki, General Manager of Oncology; and Walter Strapps, Ph.D., Executive Director of RNA Therapeutics.
Global Colitis Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 32 Drug Profiles
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zwv5t/colitis) has announced the addition of the "Colitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Colitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Colitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Colitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Colitis - Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - BioLineRx, Ltd. - Pfizer Inc. - Idera Pharmaceuticals, Inc. - Lpath, Inc. - Protalix BioTherapeutics, Inc. - Galapagos NV - Akebia Therapeutics, Inc. - NasVax Ltd. - Lycera Corp. - Zyngenia, Inc. - N30 Pharmaceuticals - Cognosci, Inc. - Atlantic Healthcare Limited - CellAct Pharma GmbH - Ajinomoto Pharmaceuticals Co., Ltd. Drug Profiles - LT-1009 - PF-06425090 - IMO-3100 - BL-5040 - VGX-1027 - N-6022 - GLPG-0634 - COG-112 - Anti-CD3 Oral Immunotherapy - etanercept biosimilar - N-6547 - BRA-101 - Bioenergetics Program - ARA-290 - CAP-2.1 - CAP-2.2 - Clostridium difficile Vaccine - Cathelicidin - IP-1510 - Helminth-Derived Peptides - Drugs to Inhibit Panx1 for Colitis - Recombinant Cholera Toxin-B - Bi-Specific Anti-TNFalpha/Ang2 Zybody - auranofin - NK-007 - Treg Cells to Inhibit TCR Antagonist for Colitis - Vaccine for Colitis and Respiratory Tract Inflammatory Disorders - APY-0201 - IL-23 P19 Vaccine - AKB-6899 For more information visit http://www.researchandmarkets.com/research/3zwv5t/colitis
Global Moderate Psoriasis Therapeutic Pipeline Review 2014 - 13 Companies Profiled, 19 Drugs Profiled
M2 - Mon Apr 28, 3:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/454xct/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. Scope: - The report provides a snapshot of the global therapeutic landscape of Moderate Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Moderate Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Moderate Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Moderate Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Johnson & Johnson - Boehringer Ingelheim GmbH - Amgen Inc. - Eli Lilly and Company - AbGenomics International, Inc. - ApoPharma Inc. - OPKO Health, Inc. - Idera Pharmaceuticals, Inc. - Almirall, S.A. - Syntrix Biosystems, Inc. - Vascular Biogenics Ltd. - GlycoMar Limited - Avexxin AS Drug Profiles - ixekizumab - LAS-41008 - IMO-3100 - AbGn-168H - VB-201 - lunacalcipol - guselkumab - Apo-805-K1 - BI-655066 - IMO-8400 - MOL-4249 - AVX-001 - AMG-811 - guselkumab - aminopterin sodium - AKP-11 - cyclosporine - GLY-198 - GLYK-5006 For more information visit http://www.researchandmarkets.com/research/454xct/moderate
Will Idera Pharmaceuticals (IDRA) Stock Sustain Today's Rally?
at The Street - Tue Apr 22, 12:21PM CDT
Idera Pharmaceuticals (IDRA) surged Tuesday on a positive day for healthcare stocks after the company had remained relatively flat since last week.
U.S. District Court Judge Nixes Banning of Zogenix's Painkiller in Massachusetts
ACCESSWIRE - Mon Apr 21, 9:42AM CDT
A U.S. District Court judge stopped Massachusetts from banning the sale of Zogenix Inc.'s (NASDAQ: ZGNX) prescription painkiller Zohydro, saying that the decision was based on the principle that federal law superseded the state's action.
Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)
at The Street - Fri Apr 11, 9:10AM CDT
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Top Gainers Technical Data -- Research on BioScrip, E-House China Holdings, MagneGas, and Idera Pharma
PR Newswire - Wed Apr 09, 7:47AM CDT
On Tuesday, April 08, 2014, the US markets saw a positive sentiment, with the NASDAQ Composite closing at 4,112.99, up 0.81%, the Dow Jones Industrial Average ending the session at 16,256.14, up 0.06%, and the S&P 500 edging 0.38% higher to finish the trading session at 1,851.96. The session saw a positive impact from Consumer Discretionary, Energy and Utilities sectors along with a drag from Health Care, Industrials and Telecommunication Services sectors. A number of stocks saw large movements, including BioScrip Inc. (NASDAQ: BIOS), E-House China Holdings Ltd (NYSE: EJ), MagneGas Corp. (NASDAQ: MNGA) and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free technical research on BIOS, EJ, MNGA and IDRA can be downloaded upon signing up at:
Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic MYD88 L265P Mutation
Business Wire - Mon Apr 07, 3:05PM CDT
--- IMO-8400 in Phase 1/2 trial for Waldenstrom's macroglobulinemia -
Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Idera Pharmaceuticals, Inc. Bouncing on Phase 2 Success
Catherine Shaffer, The Motley Fool - Motley Fool - Tue Apr 01, 5:30PM CDT
Idera Pharmaceuticals ' stock market rollercoaster ride left it partially recovered from its 25% plunge just over a week ago upon FDA approval of a competing product developed by Celgene . Idera's plaque psoriasis candidate, IMO-8400, gave good...
Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock
at The Street - Tue Apr 01, 8:48AM CDT
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Why MannKind, Momenta Pharmaceuticals, and Idera Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 31, 7:30PM CDT
Lately, the stock market has turned on every word from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from investors Monday. With Yellen offering a much more...
Idera Soars on Phase II Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:06PM CDT
Idera announced positive top-line data from a phase II study on IMO-8400.
Biggest Biotech Clinical Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 1:30PM CDT
Last week was full of great news for biotechs. Idera Pharmaceuticals finally had some luck with a troubled program. Clovis Oncology took a big step toward treating defined populations with unmet need with a drug and diagnostic combination....
